LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Diagnostic Approach Combines DNA Testing With AI Analysis for Coronary Heart Disease Risk Assessment

By LabMedica International staff writers
Posted on 10 May 2023
Print article
Image: Epi+Gen CHD is a patented next generation test that assesses near-term (3-year) risk for a heart attack (Photo courtesy of Cardio Diagnostics)
Image: Epi+Gen CHD is a patented next generation test that assesses near-term (3-year) risk for a heart attack (Photo courtesy of Cardio Diagnostics)

Although preventative health is crucial in managing cardiovascular disease, for the last three decades, healthcare professionals have had to depend on limited, one-dimensional methods to guide preventive care. Currently, primary care practitioners have only the Framingham Risk Score (FRS) and the Atherosclerotic Cardiovascular Disease (ASCVD) Risk Calculator to predict the likelihood of future heart disease. However, these tools demonstrate poor performance in both research environments and real-world practice. A novel test now merges epigenetics, genetics, high-throughput computing, and artificial intelligence to pinpoint individuals at risk for coronary heart disease, a critical factor in delivering cost-effective health care to adults.

Cardio Diagnostics Inc. (Chicago IL, USA) has developed Epi+Gen CHD as an alternative to the existing tests available. Epi+Gen CHD not only identifies those at a lower risk of developing coronary heart disease, which current tests accurately do, but also recognizes those at a higher risk, an aspect where current tests fall short. The test focuses on coronary heart disease risk since it is the most prevalent type of heart disease and the primary cause of heart attacks.

Epi+Gen CHD adopts an entirely new approach to evaluating coronary heart disease risk by integrating DNA testing of genetic and epigenetic biomarkers with AI-driven analysis to produce personalized risk profiles for each patient. The test assesses DNA methylation status at three loci and genotype at five loci. An AI-guided algorithm then interprets the DNA methylation results in relation to genetic variations. This method enables the understanding of epigenetic signatures that might otherwise be obscured by background genetic variation. As the first comprehensive and sensitive genetic-epigenetic clinical test for determining the three-year heart attack risk, Epi+Gen CHD represents the future of preventive cardiovascular disease care.

Related Links:
Cardio Diagnostics Inc. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more